Stereoselective 4-hydroxylation of debrisoquine in Nigerians. 1988

M S Lennard, and G T Tucker, and H F Woods, and A O Iyun, and M Eichelbaum
University Department of Therapeutics, Royal Hallamshire Hospital, Sheffield, U.K.

UI MeSH Term Description Entries
D007546 Isoquinolines A group of compounds with the heterocyclic ring structure of benzo(c)pyridine. The ring structure is characteristic of the group of opium alkaloids such as papaverine. (From Stedman, 25th ed)
D009549 Nigeria A republic in western Africa, south of NIGER between BENIN and CAMEROON. Its capital is Abuja. Federal Republic of Nigeria
D003647 Debrisoquin An adrenergic neuron-blocking drug similar in effects to GUANETHIDINE. It is also noteworthy in being a substrate for a polymorphic cytochrome P-450 enzyme. Persons with certain isoforms of this enzyme are unable to properly metabolize this and many other clinically important drugs. They are commonly referred to as having a debrisoquin 4-hydroxylase polymorphism. Debrisoquine,Tendor
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006899 Mixed Function Oxygenases Widely distributed enzymes that carry out oxidation-reduction reactions in which one atom of the oxygen molecule is incorporated into the organic substrate; the other oxygen atom is reduced and combined with hydrogen ions to form water. They are also known as monooxygenases or hydroxylases. These reactions require two substrates as reductants for each of the two oxygen atoms. There are different classes of monooxygenases depending on the type of hydrogen-providing cosubstrate (COENZYMES) required in the mixed-function oxidation. Hydroxylase,Hydroxylases,Mixed Function Oxidase,Mixed Function Oxygenase,Monooxygenase,Monooxygenases,Mixed Function Oxidases,Function Oxidase, Mixed,Function Oxygenase, Mixed,Oxidase, Mixed Function,Oxidases, Mixed Function,Oxygenase, Mixed Function,Oxygenases, Mixed Function
D006900 Hydroxylation Placing of a hydroxyl group on a compound in a position where one did not exist before. (Stedman, 26th ed) Hydroxylations
D013237 Stereoisomerism The phenomenon whereby compounds whose molecules have the same number and kind of atoms and the same atomic arrangement, but differ in their spatial relationships. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 5th ed) Molecular Stereochemistry,Stereoisomers,Stereochemistry, Molecular,Stereoisomer
D044383 Black People Persons having origins in any of the black racial groups of AFRICA. Note that OMB category BLACK OR AFRICAN AMERICAN is available for the United States population groups. Race and ethnicity terms, as used in the federal government, are self-identified social construct and may include terms outdated and offensive in MeSH to assist users who are interested in retrieving comprehensive search results for studies such as in longitudinal studies. African Continental Ancestry Group,Black Person,Negroid Race,Black Peoples,Black Persons,Negroid Races,People, Black,Person, Black,Persons, Black,Race, Negroid
D019389 Cytochrome P-450 CYP2D6 A cytochrome P450 enzyme that catalyzes the hydroxylation of many drugs and environmental chemicals, such as DEBRISOQUINE; ADRENERGIC RECEPTOR ANTAGONISTS; and TRICYCLIC ANTIDEPRESSANTS. This enzyme is deficient in up to 10 percent of the Caucasian population. CYP2D6,Debrisoquine 4-Hydroxylase,Debrisoquine Hydroxylase,CYP 2D6,Cytochrome P450 2D6,Debrisoquine 4-Monooxygenase,Imipramine 2-Hydroxylase,Sparteine Monooxygenase,2-Hydroxylase, Imipramine,4-Hydroxylase, Debrisoquine,4-Monooxygenase, Debrisoquine,CYP2D6, Cytochrome P-450,Cytochrome P 450 CYP2D6,Debrisoquine 4 Hydroxylase,Debrisoquine 4 Monooxygenase,Hydroxylase, Debrisoquine,Imipramine 2 Hydroxylase,Monooxygenase, Sparteine,P-450 CYP2D6, Cytochrome,P450 2D6, Cytochrome

Related Publications

M S Lennard, and G T Tucker, and H F Woods, and A O Iyun, and M Eichelbaum
January 1980, British journal of clinical pharmacology,
M S Lennard, and G T Tucker, and H F Woods, and A O Iyun, and M Eichelbaum
January 1980, British journal of clinical pharmacology,
M S Lennard, and G T Tucker, and H F Woods, and A O Iyun, and M Eichelbaum
June 1994, Pharmacogenetics,
M S Lennard, and G T Tucker, and H F Woods, and A O Iyun, and M Eichelbaum
November 1985, Lancet (London, England),
M S Lennard, and G T Tucker, and H F Woods, and A O Iyun, and M Eichelbaum
November 1991, Pharmacogenetics,
M S Lennard, and G T Tucker, and H F Woods, and A O Iyun, and M Eichelbaum
January 1981, European journal of clinical pharmacology,
M S Lennard, and G T Tucker, and H F Woods, and A O Iyun, and M Eichelbaum
January 1999, Nephron,
M S Lennard, and G T Tucker, and H F Woods, and A O Iyun, and M Eichelbaum
April 1988, British journal of clinical pharmacology,
M S Lennard, and G T Tucker, and H F Woods, and A O Iyun, and M Eichelbaum
January 1989, European journal of clinical pharmacology,
M S Lennard, and G T Tucker, and H F Woods, and A O Iyun, and M Eichelbaum
November 1980, Xenobiotica; the fate of foreign compounds in biological systems,
Copied contents to your clipboard!